Terns Pharmaceuticals, INC Schedule 13G passive stakes

Morgan Stanley has filed an amendment indicating it no longer beneficially owns more than five percent of Terns Pharmaceuticals, Inc. common stock.

Adage Capital Management, L.P. has reported beneficial ownership of 2,124,817 shares, representing 1.84% of Terns Pharmaceuticals, Inc. common stock as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amendment to their Schedule 13G, reporting changes in their beneficial ownership of Terns Pharmaceuticals, Inc. common stock.

The Vanguard Group has amended its Schedule 13G filing for Terns Pharmaceuticals Inc., reporting zero beneficial ownership following an internal realignment.

Vivo Capital entities have filed an Amendment No. 3 to Schedule 13G, disclosing their passive beneficial ownership in Terns Pharmaceuticals, Inc. common stock.

Deep Track Capital and affiliates have reduced their beneficial ownership in Terns Pharmaceuticals, Inc. to 2.97% of common stock.

Soleus Capital entities and Guy Levy report beneficial ownership of 0.2% of Terns Pharmaceuticals, Inc. common stock.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a 5.10% beneficial ownership stake in Terns Pharmaceuticals, Inc. as of December 31, 2025.

Commodore Capital LP and related entities reported a 6.5% beneficial ownership stake in Terns Pharmaceuticals, Inc., totaling 5,700,000 shares of common stock.

The Vanguard Group has reported a 5.21% beneficial ownership stake in Terns Pharmaceuticals Inc. common stock.

Commodore Capital LP and its affiliates reported a passive beneficial ownership of 5.3% in Terns Pharmaceuticals, Inc. common stock.

Deep Track Capital, LP and its affiliates, including Deep Track Biotechnology Master Fund, Ltd. and David Kroin, have reported a beneficial ownership of 8.58% in Terns Pharmaceuticals, Inc.

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting a 4.93% passive beneficial ownership stake in Terns Pharmaceuticals, Inc. as of March 31, 2025.

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 6.39% of Terns Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 8.1% of Terns Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Citadel Advisors, Citadel Securities, and Kenneth Griffin have filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 4.1% in Terns Pharmaceuticals, Inc. as of December 31, 2024.

Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 6.16% in Terns Pharmaceuticals, Inc. as of December 31, 2024.

Soleus Capital Master Fund, L.P. and its affiliated entities have filed an amended Schedule 13G, reaffirming their passive beneficial ownership of 9.6% of Terns Pharmaceuticals, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.8% beneficial ownership stake in Terns Pharmaceuticals, Inc. as of December 31, 2024, held for passive investment purposes.